Sami Inkinen

And then finally, I will say, again, there's a place for these trucks. GLP-1 is a tool in a toolkit. But I think this statement holds true, which is, We don't know the short, the midterm and the long-term side effects of exogenous drugs, but we know the side effects of healthy food. Guess what? Happier, better, longer life.

And then finally, I will say, again, there's a place for these trucks. GLP-1 is a tool in a toolkit. But I think this statement holds true, which is, We don't know the short, the midterm and the long-term side effects of exogenous drugs, but we know the side effects of healthy food. Guess what? Happier, better, longer life.

Like healthy food. It's tough to say like, what's bad about that? Not much.

Like healthy food. It's tough to say like, what's bad about that? Not much.

Like healthy food. It's tough to say like, what's bad about that? Not much.

Yeah, I would add there, Mark, that the nutrition science and the care delivery model, and the third piece that I think has been behind Virta's, what I might call early success and impact, is the business model. And it may sound like MBA talk, but this is a very, very important thing because if you don't have the right business model, you can't get anywhere in US healthcare.

Yeah, I would add there, Mark, that the nutrition science and the care delivery model, and the third piece that I think has been behind Virta's, what I might call early success and impact, is the business model. And it may sound like MBA talk, but this is a very, very important thing because if you don't have the right business model, you can't get anywhere in US healthcare.

Yeah, I would add there, Mark, that the nutrition science and the care delivery model, and the third piece that I think has been behind Virta's, what I might call early success and impact, is the business model. And it may sound like MBA talk, but this is a very, very important thing because if you don't have the right business model, you can't get anywhere in US healthcare.

And so our business model is very, very rare in U.S. healthcare in that it is a true win, win, win. So what we do is VirtaCare is 100% free. No, I'm not joking. 100% free for the individual patient. So that's a win for the patient. But then the payer that we work with, which is either self-insured employers like Fortune 500 companies like UPS or United Airlines or U.S.

And so our business model is very, very rare in U.S. healthcare in that it is a true win, win, win. So what we do is VirtaCare is 100% free. No, I'm not joking. 100% free for the individual patient. So that's a win for the patient. But then the payer that we work with, which is either self-insured employers like Fortune 500 companies like UPS or United Airlines or U.S.

And so our business model is very, very rare in U.S. healthcare in that it is a true win, win, win. So what we do is VirtaCare is 100% free. No, I'm not joking. 100% free for the individual patient. So that's a win for the patient. But then the payer that we work with, which is either self-insured employers like Fortune 500 companies like UPS or United Airlines or U.S.

Foods, like we work with nearly 500 large employers and then health plans like Brazil, California, Humana and some government entities. So the payer pays for the treatment. But here's the best part. Like you said, they save a lot of money, so they pay less for

Foods, like we work with nearly 500 large employers and then health plans like Brazil, California, Humana and some government entities. So the payer pays for the treatment. But here's the best part. Like you said, they save a lot of money, so they pay less for

Foods, like we work with nearly 500 large employers and then health plans like Brazil, California, Humana and some government entities. So the payer pays for the treatment. But here's the best part. Like you said, they save a lot of money, so they pay less for

than they save so that's the second win so it's very rare in u.s healthcare usually it's like oh this is a beautiful new molecule big molecule large molecule or like a specific cancer treatment say um And then it's million-dollar treatment or $100,000 treatment. And then there's this trade-off. Okay, clearly it's going to improve, save human lives, but can we afford to cover?

than they save so that's the second win so it's very rare in u.s healthcare usually it's like oh this is a beautiful new molecule big molecule large molecule or like a specific cancer treatment say um And then it's million-dollar treatment or $100,000 treatment. And then there's this trade-off. Okay, clearly it's going to improve, save human lives, but can we afford to cover?

than they save so that's the second win so it's very rare in u.s healthcare usually it's like oh this is a beautiful new molecule big molecule large molecule or like a specific cancer treatment say um And then it's million-dollar treatment or $100,000 treatment. And then there's this trade-off. Okay, clearly it's going to improve, save human lives, but can we afford to cover?

But in a case of reversing chronic disease like type 2 diabetes, we literally go to a large employer, again, like US Foods has been applying for a long time. And we say, guess what? We can reverse diabetes, make your employees happy and more productive. and you make money in the process, and this is safe, here's the evidence published, period. What is there not to like?

But in a case of reversing chronic disease like type 2 diabetes, we literally go to a large employer, again, like US Foods has been applying for a long time. And we say, guess what? We can reverse diabetes, make your employees happy and more productive. and you make money in the process, and this is safe, here's the evidence published, period. What is there not to like?

But in a case of reversing chronic disease like type 2 diabetes, we literally go to a large employer, again, like US Foods has been applying for a long time. And we say, guess what? We can reverse diabetes, make your employees happy and more productive. and you make money in the process, and this is safe, here's the evidence published, period. What is there not to like?